synovial sarcoma-pipeline review, h2 2017

synovial sarcoma-pipeline review, h2 2017


  • Products Id :- GMDHC9661IDB
  • |
  • Pages: 189
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Synovial Sarcoma-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma-Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 3 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).

-The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Synovial Sarcoma-Overview 6

Synovial Sarcoma-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Synovial Sarcoma-Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Synovial Sarcoma-Companies Involved in Therapeutics Development 21

Adaptimmune Therapeutics Plc 21

Advenchen Laboratories LLC 21

EpiZyme Inc 22

Immune Design Corp 22

Immunocore Ltd 23

Johnson & Johnson 23

Karyopharm Therapeutics Inc 24

Merck & Co Inc 24

Millennium Pharmaceuticals Inc 25

Novartis AG 25

Pfizer Inc 26

Takara Bio Inc 26

Synovial Sarcoma-Drug Profiles 27

ACXT-3102-Drug Profile 27

AL-3818-Drug Profile 28

axitinib-Drug Profile 31

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 37

CMB-305-Drug Profile 38

CUE-102-Drug Profile 42

everolimus-Drug Profile 43

Fusion Protein for Oncology-Drug Profile 55

GSK-3377794-Drug Profile 56

pembrolizumab-Drug Profile 66

quisinostat hydrochloride-Drug Profile 127

sapanisertib-Drug Profile 129

selinexor-Drug Profile 133

SSTC-104-Drug Profile 155

tazemetostat-Drug Profile 156

TBI-1301-Drug Profile 167

Synovial Sarcoma-Dormant Projects 168

Synovial Sarcoma-Discontinued Products 169

Synovial Sarcoma-Product Development Milestones 170

Featured News & Press Releases 170

Appendix 187

Methodology 187

Coverage 187

Secondary Research 187

Primary Research 187

Expert Panel Validation 187

Contact Us 187

Disclaimer 188

List of Figures

Number of Products under Development for Synovial Sarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Synovial Sarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Synovial Sarcoma-Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Synovial Sarcoma-Pipeline by Advenchen Laboratories LLC, H2 2017

Synovial Sarcoma-Pipeline by EpiZyme Inc, H2 2017

Synovial Sarcoma-Pipeline by Immune Design Corp, H2 2017

Synovial Sarcoma-Pipeline by Immunocore Ltd, H2 2017

Synovial Sarcoma-Pipeline by Johnson & Johnson, H2 2017

Synovial Sarcoma-Pipeline by Karyopharm Therapeutics Inc, H2 2017

Synovial Sarcoma-Pipeline by Merck & Co Inc, H2 2017

Synovial Sarcoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Synovial Sarcoma-Pipeline by Novartis AG, H2 2017

Synovial Sarcoma-Pipeline by Pfizer Inc, H2 2017

Synovial Sarcoma-Pipeline by Takara Bio Inc, H2 2017

Synovial Sarcoma-Dormant Projects, H2 2017

Synovial Sarcoma-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

EpiZyme Inc

Immune Design Corp

Immunocore Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Takara Bio Inc

select a license
Single User License
USD 2000 INR 142520
Site License
USD 4000 INR 285040
Corporate User License
USD 6000 INR 427560

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com